37. Mine T, Gouhara R, Hida N, Imai N, Azuma K, Rikimaru T, Katagiri K, Nishikori M, Sukehiro A, Nakagawa M, Yamada A, Aizawa H, Shirouzu K, Itoh K, Yamana H (2003) Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Sci 94:548–556

38. Tsuda N, Mochizuki K, Harada M, Sukehiro A, Kawano K, Yamada A, Ushijima K, Sugiyama T, Nishida T, Yamana H, Itoh K, Kamura T (2004) Vaccination with pre-designated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 27:60–67

39. Komatsu N, Shichijo S, Nakagawa M, Itoh K (2004) New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 64:535–545

40. Terasaki M, Shibui S, Narita Y, Fujimaki T, Aoki T, Kajiwara K, Sawamura Y, Kurisu K, Mineta T, Yamada A, Itoh K (2011) Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 29:337–344

41. Noguchi M, Uemura H, Naito S, Akaza H, Yamada A, Itoh K (2011) A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate 71:470–479

42. Sharma P, Wagner K, Wolchok JD, Allison JP (2011) Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer 11:805–812

43. Whiteside TL (2008) Immune monitoring of clinical trials with biotherapies. Adv Clin Chem 45:75–97

44. Mine T, Sato Y, Noguchi M, Sasatomi T, Gouhara R, Tsuda N, Tanaka S, Shomura H, Katagiri K, Rikimaru T, Shichijo S, Kamura T, Hashimoto T, Shirouzu K, Yamada A, Todo S, Itoh K, Yamana H (2004) Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 10:929–937

45. Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh U, Kawano K, Azuma K, Uemura H, Okuno K, Matsumoto Y, Yanagimoto H, Yamanaka R, Oka M, Todo S, Sasada T, Itoh K (2011) Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 10:1266–1279

46. Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S (2003) Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 57:80–92

47. Noguchi M, Itoh K, Suekane S, Morinaga A, Sukehiro A, Suetsugu N, Katagiri K, Yamada A, Noda S (2004) Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate 60:32–45

48. Noguchi M, Itoh K, Suekane S, Yao A, Suetsugu N, Katagiri K, Yamada A, Yamana H, Noda S (2004) Phase I trial of patient-oriented vaccination in HLA-A2 positive patients with metastatic hormone refractory prostate cancer. Cancer Sci 95:77–84

49. Noguchi M, Itoh K, Yao A, Mine T, Yamada A, Obata Y, Furuta M, Harada M, Suekane S, Matsuoka K (2005) Immunological evaluation of individualized peptide vaccination with a low-dose of estramustine for HLA-A24+ HRPC patients. Prostate 63:1–12

50. Noguchi M, Mine T, Yamada A, Obata Y, Yoshida K, Mizoguchi J, Harada M, Suekane S, Itoh K, Matsuoka K (2007) Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: An analysis of prognostic factors in the treatment. Oncol Res 16:341–349

51. Noguchi M, Kakuma T, Uemura H, Nasu Y, Kumon H, Hirao Y, Moriya F, Suekane S, Matsuoka K, Komatsu N, Shichijo S, Yamada A, Itoh K (2010) A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. Cancer Immunol Immunother 59:1001–1009

52. Noguchi M, Moriya F, Suekane S, Matsuoka K, Arai G, Matsueda S, Sasada T, Yamada A, Itho K (2012) Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. Prostate 72:834–845

53. Sato Y, Maeda Y, Sasatomi T, Takahashi M, Une Y, Kondo M, Shinohara T, Hida N, Katagiri K, Sato K, Sato M, Yamada A, Yamana H, Harada M, Itoh K, Todo S (2004) A phase I trial of CTL-precursor-oriented peptide vaccine for colorectal carcinoma patients. Br J Cancer 90:13334–13342

54. Sato Y, Fujiwara T, Mine T, Shomura H, Homma S, Maeda Y, Tokunaga N, Ikeda Y, Ishihara Y, Yamada A, Tanaka N, Itoh K, Harada M, Todo S (2007) Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci 98:1113–1119

55. Yanagimoto H, Mine T, Yamamoto K, Satoi S, Terakawa N, Takahashi K, Nakahara K, Homma S, Tanaka M, Mizoguchi J, Yamada A, Oka M, Kamiyama Y, Itoh K, Takai S (2007) Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 98:605–611

56. Yanagimoto H, Shiomi H, Satoi S, Mine T, Toyokawa H, Yamamoto T, Tani T, Yamada A, Kwon AH, Komatsu N, Itoh K, Noguchi M (2010) A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep 24:795–801

57. Sato Y, Shomura H, Maeda Y, Mine T, Une Y, Akasaka Y, Kondo M, Takahashi S, Shinohara T, Katagiri K, Sato M, Okada S, Matsui K, Yamada A, Yamana H, Itoh K, Todo S (2003) Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 94:802–808

58. Terazaki Y, Yoshiyama K, Matsueda S, Watanabe N, Kawahara A, Naito Y, Suekane S, Komatsu N, Ioji T, Yamada A, Mine T, Terasaki M, Itoh K, Takamori S, Sasada T (2012) Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer. Cancer Sci 103:638–644

59. Yoshiyama K, Terazaki Y, Matsueda S, Shichijo S, Noguchi M, Yamada A, Mine T, Ioji T, Itoh K, Shirouzu K, Sasada T, Takamori S (2012) Personalized peptide vaccination in patients with refractory non-small cell lung cancer. Int J Oncol 40:1492–1500

60. Suekane S, Nishitani M, Noguchi M, Komohara Y, Kokubu T, Naitoh M, Honma S, Yamada A, Itoh K, Matsuoka K, Kanayama H (2007) Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. Cancer 98:1965–1968

61. Tanaka S, Harada M, Mine T, Noguchi M, Gohara R, Azuma K, Tamura M, Yamada A, Morinaga A, Nishikori M, Katagiri K, Itoh K, Yamana H, Hashimoto T (2003) Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific cytotoxic T-lymphocyte precursors in the periphery. J Immunother 26:357–366

62. Matsumoto K, Noguchi M, Satoh T, Tabata K, Fujita T, Iwamura M, Yamada A, Komatsu N, Baba S, Itoh K (2011) A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. BJU Int 108:831–838

Review Article

Next-generation peptide vaccines for advanced cancer

Akira Yamada,[1,4] Tetsuro Sasada,[2] Masanori Noguchi[3] and Kyogo Itoh[2]

[1]Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume; [2]Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume; [3]Clinical Research Division, Kurume University Research Center for Innovative Cancer Therapy, Kurume, Japan

Many clinical trials of peptide vaccines have been carried out since the first clinical trial of a melanoma antigen gene-1-derived peptide-based vaccine was reported in 1995. The earlier generations of peptide vaccines were composed of one to several human leukocyte antigen class I-restricted CTL-epitope peptides of a single human leukocyte antigen type. Currently, various types of next-generation peptide vaccines are under development. In this review, we focus on the clinical trials of the following categories of peptide vaccines mainly published from 2008 to 2012: (i) multivalent long peptide vaccines; (ii) multi-peptide vaccines consisting of CTL- and helper-epitopes; (iii) peptide cocktail vaccines; (iv) hybrid peptide vaccines; (v) personalized peptide vaccines; and (vi) peptide-pulsed dendritic cell vaccines. (*Cancer Sci* 2013; 104: 15–21)

A cDNA-expression cloning technique to identify genes and peptides of tumor-associated antigens was first reported by van der Bruggen et al. in 1991.[1] Subsequently, a technique using autologous antibodies was introduced for identification of genes and peptides recognized by the host immune system.[2] These advanced techniques have provided a large number of antigens and peptides applicable as cancer vaccines. Many clinical trials of peptide vaccines have been carried out since the first clinical trial of a melanoma antigen gene-1 (MAGE-1)-derived peptide-based vaccine was reported in 1996 by Hu et al.[3] The earlier generations of peptide vaccines were composed of one to several human leukocyte antigen (HLA)-class I-restricted peptides of a single HLA-type. The peptides were emulsified with Montanide ISA51, a clinical grade of Freund's incomplete adjuvant, or pulsed on antigen-presenting cells and used for vaccination. Various types of new generation peptide vaccines have since been developed (Figs 1,2). In this review, we discuss the recent clinical trials of the latest generation of peptide-based cancer vaccines mainly published from 2008 to 2012.

Multivalent long peptide vaccines

The classical types of peptide vaccines only contain one to several epitope peptides, which are recognized by CTLs or helper T cells. In contrast, the mother proteins of the peptide vaccines usually contain several HLA-type restricted epitopes recognized by both CTLs and helper T cells. Although the importance of helper T cells in the induction of CTLs has been established and protein vaccines are able to induce both CTLs and helper T cells, the protein vaccines have several demerits in terms of manufacturing and safety controls. To avoid these drawbacks, synthetic long peptide vaccines have been developed. Synthetic long peptide vaccines are predominantly taken up by antigen presenting cells (APCs), where they are processed for presentation by both MHC class I and II molecules.

Several clinical studies using mixes of synthetic long peptides have been reported, as mixes of synthetic long peptide are likely to contain multiple HLA class I and II T-cell epitopes, which allows the use of this type of peptide vaccine in all patients irrespective of the type of HLA of each patient. Kenter et al.[4] carried out a phase I study of high-risk type human papilloma virus (HPV) 16 E6 and E7 overlapping long peptides in end-stage cervical cancer patients. Cocktails of nine E6 peptides and/or four E7 peptides, each 25–35-mer, covering the entire sequences of E6 and E7 proteins, were given s.c. with Montanide ISA51 four times at 3-week intervals. Co-injection of E6 and E7 long peptides induced a strong and broad T-cell response dominated by immunity against E6. Subsequently, they carried out a phase II study of this vaccine in patients with HPV-positive grade 3 vulvar intraepithelial neoplasia.[5] Vulvar intraepithelial neoplasia is a chronic disorder caused by HPV 16. At 3 months after the last vaccination, 12 of 20 patients (60%) had clinical responses and reported relief of symptoms. Five women had complete regression of the lesions. At 12 months of follow-up, 15 of 19 patients (79%) had clinical responses with a complete response in 9 of 19 patients (47%).

A synthetic long peptide vaccine targeted for p53 was reported by Speetjens et al.[6] The p53 synthetic long peptide vaccine consisted of 10 synthetic 25–30-mer long overlapping peptides, spanning amino acids 70–248 of the wild type p53 protein. Ten patients with metastatic colorectal cancer were vaccinated with this vaccine. The p53-specific T cell responses were induced in 9 of 10 patients as measured by γ-interferon (IFN-γ). Subsequently, a phase II study of a p53 synthetic long overlapping peptide vaccine in patients with ovarian cancer was carried out by the same group.[7] Twenty patients with recurrent elevation of CA-125 were immunized with the vaccine. Stable disease, as determined by CA-125 levels and computed tomography scans, was observed in 2/20 (10%) patients as the best clinical response, but no relationship was found with vaccine-induced immunity. Interferon-γ-producing p53-specific T-cell responses were induced in all patients who received all four immunizations. Interestingly, the IFN-γ secreted cells were CD4 T-cells and no CD8 T-cell/CTL responses were detected. The absence of CD8 T-cell/CTL responses may be attributable to the dominant production of

[4]To whom correspondence should be addressed.
E-mail: akiymd@med.kurume-u.ac.jp

Fig. 1. Transition of peptide vaccine development for advanced cancer. DC, dendritic cells.


Fig. 2. Various types of latest generation peptide vaccines. The number of syringes indicates that of the final preparation for injection. Green, CTL-epitopes; orange, helper-epitopes. DC, dendritic cells.


Fig. 3. Personalized peptide vaccine. In the classical type of vaccine, peptides derived from tumor-specific or overexpressed antigens are used as vaccine peptides and often mismatched to the pre-existing immunity of patients. In personalized peptide vaccines, appropriate peptides for vaccination are screened and selected from a panel of vaccine candidates in each patient, based on pre-existing host immunity and HLA types.

Th2 cytokines, whose inhibitory effects on CTL induction are well known, although the vaccine immunization resulted in the expansion of p53-specific Th1 and Th2 CD4 T-cell responses.

Kakimi et al.[8] carried out a phase I trial of an NY-ESO-1 synthetic long peptide vaccine. A 20-mer NY-ESO-1f peptide, which includes multiple epitopes recognized by antibodies, and CD4 and CD8 cells, was given along with OK-432 and Montanide ISA51 to patients with advanced cancers. Both CD4 and CD8 T cell responses, as well as NY-ESO-1 antibody, were increased or induced in 9 of 10 patients.

Multipeptide vaccines consisting of CTL- and helper-epitopes

As mentioned above, helper T cells play crucial roles in the induction of CTLs. Some of the latest generation of peptide vaccines consist of HLA class-II restricted helper epitope peptides recognized by CD4 T cells in addition to class-I restricted CTL-epitope peptides to induce both CTLs and helper T cells. Numerous helper epitopes had been identified from the same target molecules of CTL-epitope vaccines and co-used as cancer vaccines.[9–17] A helper epitope peptide

capable of binding pan HLA-DR (pan-DR epitope [PADRE]) has been reported,[18] and a clinical trial of a peptide vaccine using this helper epitope was reported. Kuball et al.[15] carried out a phase I study of CTL-epitope peptides of Wilms' tumor gene, proteinase 3, and mucin 1, and PADRE or mucin 1-helper epitope peptide with Montanide ISA51 and CpG oligonucleotide. Each peptide was formulated independently of the others and injected at a separate site. An increase in PADRE-specific CD4 T cells was observed after vaccination but these appeared unable to produce interleukin 2 (IL2), and the regulatory T cells were increased. This study indicates that helper epitope peptides have the potential to induce both helper T cells and regulatory T cells.

Peptide cocktail vaccines

Different peptides have different binding affinities to the corresponding HLA molecules. Therefore, if different CTL-epitope peptides with different binding affinities are loaded to APCs, there may be competition among the individual peptides to bind HLA molecules on the APCs. To prevent this, individual peptides of multipeptide vaccines were formulated independently of each other and injected at separate sites in most of the former clinical trials. In our case, a maximum of four peptides were individually mixed with Montanide ISA51 and injected s.c. at different sites on the same day. The maximum number of four peptides was similar to the maximum acceptable number of doses for patients on the same day, and no more than five peptides were used for vaccination. One of the strategies for overcoming the limitation of peptide number is the use of multipeptide cocktail vaccines. The multipeptide cocktail vaccines have no limitation of peptide number, as one preparation can contain more than 10 peptides. However, the issue of competition between the individual peptides of a cocktail vaccine for the binding of HLA molecules on the APCs still remains.

Different types of multipeptide cocktail vaccines have been developed, that is, vaccines consisting of CTL-epitope peptides alone,[19–21] or CTL-epitope and helper-epitope peptides.[9–13,16,17] The number of component peptides in the cocktail vaccines varies from around four to more than 10. Barve

Table 1. Immunological and clinical responses to personalized peptide vaccines for advanced cancer

Disease status	Phase	HLA restriction	Total no. of patients	Humoral response (%)	Cellular response (%)	Clinical response (%)	MST (months)	Grade 3/4 toxicities	Ref. no.
Advanced CRPC	PI	A24	10	60	40	SD 50	Not ref.	0	31
Advanced CRPC	PI	A24	13	91	55	PR 63	24	G3, 5%	32
Advanced CRPC	PI	A2	10	70	40	SD 30	22	0	33
Advanced CRPC	PI/II	A24	16	50	71	PR 43	17	0	37
Advanced CRPC	PI/II	A2/A24	58	88	78	PR 24	17	G3, 7%	38
Localized PC	PII	A24	10	80	80	PR 20	Not ref.	0	39
Advanced CRPC	PI, extension	A24	15	47	67	PR 13	24	0	46
Advanced CRPC	PII, randomized	A2/A24	57	64	50	PFS 8.5 (vaccine) vs 2.8M (control)	22.4 (vaccine) vs 16.1M (control)	0	44
Advanced CRPC	PII	A2/A24/A3sup/A26	42	44	34	PR 12	17.8	0	49
Advanced malignant glioma	PI	A2/A24	21	40–64	50–82	PR 24, SD 38	Not reached	0	36
Advanced glioblastoma multiforme	PI, extension	A24	12	17	75	PR 17, SD 42	10.6	0	47
Advanced corolectal cancer	PI	A24	10	70	50	PR 10	Not ref.	0	34
Advanced corolectal cancer	PI/II	A2/A24	7	71	57	SD 14	Not ref.	G3, 20%	40
Advanced pancreatic cancer	PI	A2/A24	13	69	69	PR 15, SD 54	7.6	0	41
Non-resectable pancreatic cancer	PII	A2/A24	21	72	78	PR 33, SD 43	9	0	45
Advanced gastric cancer	PI	A2/A24	13	80	50	SD 45	Not ref.	0	30
Advanced lung cancer	PI	A24	10	40	40	SD 80	15.2	0	29
Refractory SCLC	PII	A2/A24/A3sup/A26	10	83	83	SD 20	6.2	G3, 4%	50
Refractory NSCLC	PII	A2/A24/A3sup/A26	41	49	34	SD 56	10.1	G3, 7%	42
Metastatic RCC	PI	A2/A24	10	80	5	SD 60	23	0	43
Malignant melanoma	PI	A2/A24	7	57	86	SD 43	Not ref.	0	28
Recurrent gynecologic cancer	PI	A2/A24	14	86	85	SD 36	Not ref.	G3, 8%	35
Advanced urotherial cancer	PI	A2/A24	10	80	80	CR 10, PR 10	24	0	48

A3sup, A3 super type; CR, complete response; CRPC, castration-resistant prostate cancer; G3, grade 3; HLA, human leukocyte antigen; M, months; MST, median survival time; Not ref., not referred; NSCLC, non-small-cell lung cancer; PI, phase I clinical trial; PII, phase II clinical trial; PC, prostate cancer; PD, progressive disease; PFS, progression-free survival; PR, partial response; RCC, renal cell carcinoma; Ref., reference; SCLC, small-cell lung cancer; SD, stable disease.

Fig. 4. Randomized phase II trial of personalized peptide vaccine (PPV) plus low-dose estramustine phosphate (EMP) versus standard-dose EMP in patients with castration-resistant prostate cancer. Patients were randomized into groups receiving either PPV plus low-dose EMP (280 mg/day) or standard-dose EMP (560 mg/day). (A) Duration of progression-free survival in the first treatment. (B) Overall survival of patients treated with PPV plus low-dose EMP and standard-dose EMP. CI, confidence interval.

et al.[9] carried out a phase I/II study of a cocktail vaccine IDM-2101 consisting of nine CTL-epitope peptides and the PADRE helper-epitope peptide with Montanide ISA51 in patients with metastatic non-small-cell lung cancer. No significant adverse events were noted except for low-grade erythema and pain at the injection site. One-year survival in the treated patients was 60%, and median overall survival was 17.3 months. One complete response case was observed in the total of 63 patients. Feyerabend and colleagues reported cocktail vaccines for patients with prostate cancer.[12] The cocktail vaccine consisted of 13 synthetic peptides, 11 HLA-A*0201 restricted CTL epitopes and two helper epitopes derived from prostate tumor antigens. A phase I/II trial of the vaccine was carried out in HLA-A2-positive patients with hormone-sensitive prostate cancer with biochemical recurrence after primary surgical treatment. The same group also developed another cocktail vaccine for renal cell cancer.[17] The vaccine, IMA901, consisted of nine HLA-A*0201 restricted CTL-epitopes and one helper epitope from renal cell cancer antigens with hepatitis B virus epitope as a marker peptide. A randomized phase II trial with a single dose of cyclophosphamide reduced the number of regulatory T cells and confirmed that immune responses to the vaccine component peptides were associated with longer overall survival.

Hybrid peptide vaccines

Peptide sequences of most of the single epitope vaccines as well as multi-epitope long peptide vaccines are native sequences with or without modification of anchor amino acids. Some of the latest generation of peptide vaccines are of hybrid-type, that is, a peptide fused with two epitopes. The Ii-Key/HER-2/neu hybrid peptide vaccine is a fusion peptide made up of the Ii-Key 4-mer peptide and human epidermal growth factor receptor-2 (HER-2)/neu (776–790) helper epitope peptide.[22,23] The Ii protein catalyzes direct charging

Table 2. Pros and cons of the latest generation of peptide vaccines

Vaccine type	Pros						Cons					
	Induction of CTL	Induction of Th	Applicable for multi-HLA type	Activation of memory T-cells	High efficiency of antigen presentation	Synthetic chemicals	No induction of Th	Possible induction of Treg	Not applicable for multi-HLA type	Multi formula	Induction of primary response	Biologics
Long peptide vaccine	Yes	Yes	Yes	No	No	Yes	No	Yes	No	No	Yes	No
Multipeptide non-cocktail vaccine	Yes	Yes	Yes	No	No	Yes	No	Yes	No	Yes	Yes	No
Peptide cocktail vaccine	Yes	Yes	Yes	No	No	Yes	No	Yes	No	No	Yes	No
Hybrid peptide vaccine	Yes	Yes		No	No	Yes	No	Yes	Yes	No	Yes	No
Personalized peptide vaccine	Yes	No	Yes	Yes	No	Yes	Yes	No	No	Yes	No	No
Peptide-pulsed DC vaccine	Yes	No	No	No	Yes	No	Yes/No	No	Yes	No	Yes	Yes

DC, dendritic cell; HLA, human leukocyte antigen; Th, helper T-cells; Treg, regulatory T-cells.

of MHC class II epitopes to the peptide-binding groove, circumventing the need for intracellular epitope processing, and the shortest active sequence of the Ii protein is the Ii/Key peptide.[24] Holmes et al.[22] and Perez et al. [23] reported the results of phase I studies of the Ii-Key/HER -2/neu hybrid peptide vaccine in patients with prostate cancer. Significant decreases in circulating regulatory T cell frequencies, plasma HER-2/neu, and serum transforming growth factor-β levels were observed when compared with the native HER-2/neu (776–790) peptide vaccination.

Takahashi and colleagues developed a hybrid peptide of a helper-epitope and CTL-epitope of MAGE-A4.[25] The phase I study of the vaccine was carried out in patients with advanced cancers who were vaccinated with MAGE-A4-H/K-HELP combined with OK432 and Montanide ISA51. In a case report, there were no severe side-effects except for a skin reaction at the injection site. The vaccine induced MAGE-A4-specific Th1 and Tc1 immune responses and the production of MAGE-A4-specific complement-fixing IgG antibodies. Tumor growth and the carcinoembryonic antigen tumor marker were significantly decreased in the final diagnosis.

Personalized peptide vaccines

Virtually all prevaccination patients already have a weak immunity to cancer cells. However, the characteristics of cancer cells and of the immunological status against cancers differ widely among patients, even among those with the same histological types of cancer and identical HLA types. One of the reasons for the low clinical efficacies of the earlier generations of peptide vaccines might be a mismatch between the vaccine peptides and pre-existing immunity to the cancer cells. We therefore attempted to optimize the vaccine peptides so that they were appropriately matched to the pre-existing immunity of each patient (Fig. 3). There are two ways to detect pre-existing immunity, detection of CTL-precursors and detection of IgG in the peripheral blood. The PBMCs were cultured with vaccine peptide panels and the CTL responses to each peptide were measured. The second method is to detect IgG antibodies to the vaccine peptide panels. It is well known that the production of the IgG class of antibodies requires T-cell help. Therefore, the presence of a specific IgG indicates the presence of helper T cells. We carried out a series of clinical trials using personalized peptide vaccines (PPVs) for advanced cancer patients.[26–50] In this PPV formulation, appropriate peptide antigens for vaccination are screened and selected from a panel of vaccine candidates in each patient, based on pre-existing host immunity as mentioned above. Currently, we use 31 HLA class I-restricted peptide candidates, which were identified from a variety of tumor-associated antigens mainly through the cDNA expression cloning method with tumor-infiltrating T-lymphocyte lines, 12 peptides for HLA-A2, 14 peptides for HLA-A24, 9 peptides for HLA-A3 supertype (A3, A11, A31, or A33), and 4 peptides for HLA-A26. The safety and potential immunological effects of these vaccine candidates have been shown in previous clinical studies.[26,27] A maximum of four peptides, which were selected based on the results of HLA typing and the pre-existing immune responses specific to each of the 31 different vaccine candidates, were injected s.c. with Montanide ISA51 weekly or bi-weekly.

Currently, we evaluate the pre-existing immune responses to vaccine candidates by B cell responses, but not by T cell responses, as the performance characteristics, such as the sensitivity and reproducibility, of the current T cell assays are far from satisfactory. In contrast to these drawbacks inherent to T cell assays, B cell assays have more potential for screening and/or monitoring antigen-specific immune responses even to HLA class I-restricted peptides. For example, we have

recently published several papers describing the clear correlations between clinical benefits and antigen-specific B cell responses measured by IgG antibody production in patient plasma after vaccination. Notably, the multiplex bead-based Luminex technology that we have developed for monitoring B cell responses allow simple, quick, and highly reproducible high-throughput screening of IgG responses specific to large numbers of peptide antigens with a tiny amount of plasma.

In the clinical trials of PPV carried out during the past decade, we have shown promising results in various types of cancers.[26–50] Table 1 shows the summary of the immunological and clinical responses in 460 advanced cancer patients who received PPV. The best clinical responses assessed in the 436 evaluable patients were a partial response in 43 patients (10%), stable disease in 144 patients (33%), and progressive disease in 249 patients (57%), with a median overall survival of 9.9 months. Of note, a recent phase II randomized clinical trial of PPV for 57 castration-resistant prostate cancer patients showed that patients receiving PPV in combination with low-dose estramustine phosphate (EMP) showed a significantly longer progression-free (median survival time, 8.5 months vs 2.8 months; hazard ratio, 0.28 [95% confidence interval, 0.14–0.61]; P = 0.0012) and overall survival (median survival time, undefined vs 16.1 months; hazard ratio, 0.30 [95% confidence interval, 0.1–0.91]; P = 0.0328) than those receiving standard-dose EMP alone, suggesting the feasibility of this combination therapy (Fig. 4).[44] In addition, PPV was also used in an early phase clinical trial of patients with recurrent or progressive glioblastoma multiforme, one of the most aggressive brain tumors, with a median overall survival of 10.6 months.[47] Based on these promising results, randomized phase III trials are currently underway in glioblastoma. To prove the clinical benefits of PPV for accelerating cancer vaccine development, further randomized phase III trials would also be recommended in other types of cancers.

Peptide-pulsed dendritic cell vaccines

Many clinical trials of dendritic cell (DC)-based vaccinations using autologous DC and tumor-associated antigen peptides have been carried out to assess the ability of these vaccines to induce clinical responses in cancer patients.[51–54] Rahma et al.[54] carried out a comparative study of DC-based vaccine versus non-DC-based authentic peptide vaccine. Twenty-one advanced ovarian cancer patients were divided two groups: arm A received a p53 CTL-epitope peptide with Montanide with IL2; arm B received the same peptide-pulsed DCs with IL2. The median progression-free survival and overall survival were 4.2 (arm A) i 8.7 (arm B) months and 40.8 (arm A) versus 29.6 (arm B) months, respectively. This study suggests that the simple peptide vaccination and labor-consuming DC-based vaccination therapy are similarly effective.

Conclusion

Many investigators have attempted to develop more effective cancer vaccines, and in this review we discussed the resulting progress in the latest generation of peptide vaccines. The pros and cons of each type of vaccine are shown in Table 2. Each study used different adjuvants, cytokines, and/or other combination therapies with different doses. Moreover, the individual peptides themselves had different immunological and clinical potency as well as different amino acid sequences. Therefore, it is very hard to conclude that one type of vaccine was more efficient than another. The role of immune checkpoint molecules, such as CTLA-4 and programmed cell death-1, on antitumor immunity was clarified, and promising results have been reported in the clinical trials using combination therapies

with peptide vaccines and immune checkpoint blockades.[55–57] Further randomized phase III trials would be essential to prove the clinical benefits of these vaccine therapies, including immune checkpoint blockade combination therapies.

Disclosure Statement

References

1 van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643–7.

2 Chen YT, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A 1997; 94: 1914–8.

3 Hu X, Chakraborty NG, Sporn JR, Kurtzman SH, Ergin MT, Mukherji B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. Cancer Res 1996; 56: 2479–83.

4 Kenter GG, Welters MJ, Valentijn AR et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008 (Jan 1); 14 (1): 169–77.

5 Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361: 1838–47.

6 Speetjens FM, Kuppen PJ, Welters MJ et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 2009; 15: 1086–95.

7 Leffers N, Vermeij R, Hoogeboom BN et al. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer. Int J Cancer 2012 (Jan 1); 130 (1): 105–12. doi:10.1002/ijc.25980.

8 Kakimi K, Isobe M, Uenaka A et al. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int J Cancer 2011; 129: 2836–46.

9 Barve M, Bender J, Senzer N et al. Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. J Clin Oncol 2008; 26: 4418–25.

10 Chianese-Bullock KA, Irvin WP Jr, Petroni GR et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother 2008; 31: 420–30.

11 Slingluff CL Jr, Petroni GR, Olson WC et al. Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res 2009; 15: 7036–44.

12 Feyerabend S, Stevanovic S, Gouttefangeas C et al. Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009; 69: 917–27.

13 Maslak PG, Dao T, Krug LM et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010; 116: 171–9.

14 Krug LM, Dao T, Brown AB et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 2010; 59: 1467–79.

15 Kuball J, de Boer K, Wagner E et al. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with Montanide-ISA51 and CpG7909. Cancer Immunol Immunother 2011; 60: 161–71.

16 Slingluff CL Jr, Petroni GR, Chianese-Bullock KA et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 2011; 29: 2924–32.

17 Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012 (Jul 29). doi: 10.1038/nm.2883. [Epub ahead of print].

18 Alexander J, Sidney J, Southwood S et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994; 1 : 751–61.

19 Slingluff CL Jr, Petroni GR, Chianese-Bullock KA et al. Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 2007; 13 : 6386–95.

20 Meyer RG, Korn S, Micke P et al. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer. Lung Cancer 2007; 58(1): 88–94.

21 Morse MA, Secord AA, Blackwell K et al. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clin Cancer Res 2011; 17: 3408–19.

22 Holmes JP, Benavides LC, Gates JD et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008; 26: 3426–33.

23 Perez SA, Kallinteris NL, Bisias S et al. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776–790) hybrid peptide vaccine in patients with prostate cancer. Clin Cancer Res 2010; 16: 3495–506.

24 Kallinteris NL, Lu X, Blackwell CE, von Hofe E, Humphreys RE, Xu M. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines. Expert Opin Biol Ther 2006; 6: 1311–21.

25 Takahashi N, Ohkuri T, Homma S et al. First clinical trial of cancer vaccine therapy with artificially synthesized helper/killer-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Sci 2012 (Jan); 103 (1): 150–3. doi:10.1111/j.1349-7006.2011.02106.x.

26 Itoh K, Yamada A. Personalized peptide vaccines: a new therapeutic modality for cancer. Cancer Sci 2006; 97: 970–6.

27 Itoh K, Yamada A, Mine T, Noguchi M. Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol 2009; 39: 73–80.

28 Tanaka S, Harada M, Mine T et al. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific cytotoxic T-lymphocyte precursors in the periphery. J Immunother 2003; 26: 357–366.

29 Mine T, Gouhara R, Hida N et al. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Sci 2003; 94: 548–556.

30 Sato Y, Shomura H, Maeda Y et al. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide. Cancer Sci 2003; 94: 802–808.

31 Noguchi M, Kobayashi K, Suetsugu N et al. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 2003; 57: 80–92.

32 Noguchi M, Itoh K, Suekane S et al. Immunological monitoring during combination of patient-oriented peptide vaccination and estramustine phosphate in patients with metastatic hormone refractory prostate cancer. Prostate 2004; 60: 32–45.

33 Noguchi M, Itoh K, Suekane S et al. Phase I trial of patient-oriented vaccination in HLA-A2 positive patients with metastatic hormone refractory prostate cancer. Cancer Sci 2004; 95: 77–84.

34 Sato Y, Maeda Y, Shomura H et al. A phase I trial of cytotoxic T-lymphocyte precursor-oriented peptide vaccines for colorectal carcinoma patients. Br J Cancer 2004; 90: 13334–13342.

35 Tsuda N, Mochizuki K, Harada M et al. Vaccination with pre-designated or evidence-based peptides for patients with recurrent gynecologic cancers. J Immunother 2004; 27: 60–67.

36 Yajima N, Yamanaka R, Mine T et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 2005; 11: 5900–5911.

37 Noguchi M, Itoh K, Yao A et al. Immunological evaluation of individualized peptide vaccination with a low-dose of estramustine for HLA-A24+ HRPC patients. Prostate 2005; 63: 1–12.

38 Noguchi M, Mine T, Yamada A et al. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. Oncol Res 2007; 16: 341–349.

39 Noguchi M, Yao A, Harada M et al. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer. Prostate 2007; 67: 933–942.

40 Sato Y, Fujiwara T, Mine T et al. Immunological evaluation of personalized peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for advanced gastric or colorectal carcinoma patients. Cancer Sci 2007; 98: 1113–1119.

41 Yanagimoto H, Mine T, Yamamoto K et al. Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. Cancer Sci 2007; 98: 605–611.

42 Yoshiyama K, Terazaki Y, Matsueda S *et al.* Personalized peptide vaccination in patients with refractory non-small cell lung cancer. *Int J Oncol* 2012; **40**: 1492–500.
43 Suekane S, Nishitani M, Noguchi M *et al.* Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients. *Cancer* 2007; **98**: 1965–1968.
44 Noguchi M, Kakuma T, Uemura H *et al.* A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. *Cancer Immunol Immunother* 2010; **59**: 1001–1009.
45 Yanagimoto H, Shiomi H, Satoi S *et al.* A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. *Oncol Rep* 2010; **24**: 795–801.
46 Noguchi M, Uemura H, Naito S, Akaza H, Yamada A, Itoh K. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. *Prostate* 2011; **71**: 470–479.
47 Terasaki M, Shibui S, Narita Y *et al.* Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen–A24 with recurrent or progressive glioblastoma multiforme. *J Clin Oncol* 2011; **29**: 337–344.
48 Matsumoto K, Noguchi M, Satoh T *et al.* A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin. *BJU Int* 2011; **108**: 831–8.
49 Noguchi M, Moriya F, Suekane S *et al.* Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. *Prostate* 2012; **72**: 834–45.
50 Terazaki Y, Yoshiyama K, Matsueda S *et al.* Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer. *Cancer Sci* 2012; **103**: 638–44.
51 Svane IM, Pedersen AE, Johansen JS *et al.* Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. *Cancer Immunol Immunother* 2007; **56**: 1485–99.
52 Kavanagh B, Ko A, Venook A *et al.* Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. *J Immunother* 2007; **30**: 762–72.
53 Okada H, Kalinski P, Ueda R *et al.* Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. *J Clin Oncol* 2011; **29**: 330–6.
54 Rahma OE, Ashtar E, Czystowska M *et al.* A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. *Cancer Immunol Immunother* 2012; **61**: 373–84.
55 Hodi FS, O'Day SJ, McDermott DF *et al.* Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010; **363**: 711–23. Epub 2010 Jun 5. Erratum in: N Engl J Med. 2010;363(13):1290.
56 Yuan J, Ginsberg B, Page D *et al.* CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases. *Cancer Immunol Immunother* 2011; **60**: 1137–46.
57 Sarnaik AA, Yu B, Yu D *et al.* Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. *Clin Cancer Res* 2011; **17**: 896–906.

FINAL

1

Personalized Peptide Vaccine for Treatment of Advanced Cancer

Tetsuro Sasada[1,*], Akira Yamada[2], Masanori Noguchi[2,3] and Kyogo Itoh[1]

[1]Department of Immunology and Immunotherapy, Kurume University School of Medicine, Kurume, Japan; [2]Research Center for Innovative Cancer Therapy, Kurume University, Kurume, Japan; [3]Department of Urology, Kurume University School of Medicine, Kurume, Japan

Abstract: The field of cancer immunotherapy has moved forward drastically in the past 20 years, since many tumor-associated antigens (TAA) have been identified. Although various approaches for therapeutic cancer immunotherapies, including peptide-based vaccines, have been developed and clinically examined, the complexity and diversity of tumor cell characteristics and host immune cell repertoires seem to limit the therapeutic efficacy of this treatment modality. Considering the diversity of immune responses against heterogeneous tumor cells, tailored selections of vaccine antigens appropriate for individual patients could be a rational approach for developing effective cancer vaccines. We have developed a novel immunotherapeutic approach called personalized peptide vaccine (PPV), in which a maximum of four human leukocyte antigen (HLA)-matched vaccine peptides were selected based on the pre-existing host immunity before vaccination. We conducted a series of phase I and phase II clinical trials of PPV, which have shown better antigen-specific immune responses and promising clinical outcomes in patients with various types of advanced cancers. Further randomized phase III trials would be recommended to prove the clinical benefits of PPV. In addition, novel biomarkers for selecting patients who would benefit most from PPV remain to be identified.

Keywords: Advanced cancer, biomarker, cancer immunotherapy, clinical trial, peptide epitope, personalized peptide vaccine.

1. INTRODUCTION

The field of cancer immunology and immunotherapy has moved forward drastically in the past 20 years, since many different tumor-associated antigens (TAA) have been identified [1-5]. Various approaches for therapeutic cancer immunotherapies have been developed and clinically examined, including cancer vaccines using tumor cells, proteins, peptides, viral vectors, DNA, or dendritic cells, and great advances have been made in the clinical efficacy of cancer immunotherapy [1-5]. Notably, two novel immunotherapeutic agents have recently been approved by the US Food and Drug Administration (FDA) for patients with advanced cancer [6, 7]. In April 2010, sipuleucel-T (Provenge; Dendreon Corporation, Seattle, WA), an autologous antigen-presenting cell (APC) product designed to stimulate antigen-specific immune responses against human prostatic acid phosphatase (PAP), was approved for the first time by the US FDA for the treatment of patients with castration-resistant prostate cancer (CRPC). The FDA granted this approval after treatment with sipuleucel-T improved overall survival by 4.1 months [mean survival time (MST), 25.8 months vs 21.7 months] in the largest phase 3 randomized controlled trial (the IMPACT study) [6]. In addition, in March 2011 the FDA approved ipilimumab (Yervoy; Bristol-Meyers Squibb, Princeton, NJ), an immunomodulating antibody that blocks cytotoxic T-lymphocyte antigen 4 (CTLA-4), one of the immune checkpoint molecules in T cells, to treat advanced

melanoma patients. In the phase III randomized controlled trial, this agent resulted in a 3-month improvement in overall survival with a disease control rate of 28.5%, where 60% of the responding patients maintained disease control for more than 2 years [7].

Moreover, there have been promising results in immunotherapeutic approaches to the treatment of various types of advanced cancers, although they have not yet been officially approved. For example, blocking antibodies against a T-cell co-inhibitory receptor, programmed death 1 (PD-1), and one of its ligands, PD-ligand 1 (PD-L1), which have been reported to contribute to tumor cell escape from host immune surveillance, have shown feasible results against various types of cancers [8, 9]. Topalian *et al.* demonstrated that anti-PD-1 antibody revealed objective responses in approximately 20 to 25% of patients with non-small-cell lung cancer (NSCLC), melanoma, or renal-cell cancer [8]. Brahmer *et al.* reported that anti-PD-L1 antibody, which blocks the interaction between PD-1 and PD-L1, could induce durable tumor regression (objective response rates of 6% to 17%) and prolonged stabilization of disease (12% to 41% of patients at 24 weeks) in patients with advanced cancers, including NSCLC, melanoma, and renal-cell cancer [9]. Currently, these promising advancements are generating great optimism and heightened enthusiasm for the further development of cancer immunotherapies.

In addition to these significant advances, many other clinical trials of cancer immunotherapies have been under way to show beneficial therapeutic effects in patients compared to existing treatments [1-5]. In this review, we discuss the recent advances in peptide-based cancer vaccines. In par-

*Address correspondence by this authors at the Department of Immunology and Immunotherapy, Kurume University School of Medicine, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan; Tel: +81-942-31-7551; Fax: +81-942-31-7699; E-mail: tsasada@med.kurume-u.ac.jp.

ticular, we describe the details of our novel immunotherapeutic approach, called the personalized peptide vaccine (PPV), which has demonstrated promising results for advanced cancer patients in a series of clinical trials.

## 2. PERSONALIZED PEPTIDE VACCINE (PPV)

In 1991, Boon *et al.* for the first time reported a cDNA-expression cloning technique to identify TAA [10]. Subsequently, serologic analysis of recombinant cDNA expression libraries (SEREX), another technique for detecting TAA using autologous antibodies, was introduced for the identification of genes recognized by the host immune system [11]. Such advancement of molecular biological and immunological techniques has helped identify a large number of TAA and peptide epitopes applicable as cancer vaccines [12-14]. Since 1995, when Hu *et al.* reported the first clinical trial of the vaccination of a peptide derived from melanoma antigen gene-1 (MAGE-1) [15], many clinical trials of peptide vaccines have been reported [16, 17]. In earlier stages of clinical trials of peptide vaccines, one to several human leukocyte antigen (HLA) class I-restricted peptides emulsified with Montanide ISA51, a clinical grade of Freund's incomplete adjuvant, were employed. Although the early phase clinical trials demonstrated the feasibility and good toxicity profile of this approach, most of the late-phase randomized trials, other than few exceptions [18], failed to show beneficial therapeutic effects in patients compared to existing treatments [16, 17]. Therefore, a variety of new types of peptide-based vaccines have been developed [19, 20] (Fig. 1). We first discuss our novel peptide-based approach, PPV, in which multiple vaccine antigens appropriate for each patient are selected from a panel of vaccine candidates based on pre-existing host immunity.

## 2.1. Rationale for Personalized Selections of Vaccine Peptides

Cancer patients possess anti-tumor immunity, which may depend strongly on both the tumor cell characteristics and the immunological status of the host [21-24]. The anti-tumor immunity might differ widely among individuals, since the tumor cell characteristics and the host immune cell repertoires are quite diverse and heterogeneous among patients, even among those with identical HLA types and the same pathological types of cancer. Nevertheless, before patients are enrolled in clinical trials of cancer vaccines, the expressions of vaccine antigens in tumor cells are sometimes confirmed, but the immunological statuses of the hosts are rarely evaluated. Considering the complexity and diversity of the host immune cell repertoires, it is likely that vaccine antigens that are selected and administered without considering the host immunological status might not efficiently induce beneficial anti-tumor immune responses [24]. Since, in most clinical trials of therapeutic cancer vaccines, common antigens are employed for vaccination independently of the immunological status of patients [16, 17], the low clinical efficacies might be explained at least in part by mismatches between the vaccine antigens and the host immune cell repertoires.

To evaluate the host immune cell repertoires, we examine patients' pre-existing immunity to a panel of vaccine candidates before vaccination and select appropriate vaccine antigens with immunological memory in each patient [25]. Vaccine antigens, to which patients already possess antigen-specific immunological memory, are expected to cause quick and strong secondary immune responses after vaccination (Fig. 2). In contrast, vaccinations with inadequate antigens without immunological memory could not easily provide


Fig. (1). **Recent development of new types of peptide-based vaccines.** Examples of new types of peptide-based vaccines are shown. Gray and black boxes indicate CTL and helper T-cell epitopes, respectively.

Fig. (2). Rationale of personalized peptide vaccine. In conventional peptide vaccines without pre-existing immunity, patients without immunological memory to vaccine antigens would take more time to develop effective anti-tumor immune responses because several rounds of repeated vaccinations might be required to prime antigen-specific naive T cells to functional effector cells. In personalized peptide vaccines with the pre-existing immunity, patients with antigen-specific immunological memory are expected to show quick and strong secondary immune responses to them.

clinical benefits, especially in advanced cancer patients who show rapid disease progression [26]. In light of this, it would be quite reasonable to select vaccine antigens on the basis of the pre-existing immune cell repertoires in each patient.

Cancer cells can develop various mechanisms to accelerate malignant behavior [21]. For example, it has been well recognized that cancer cells might escape the host's immunological surveillance. After the interaction/competition between tumor cells and host immune cells, tumor cell variants resistant to the immunological pressure often emerge through the selection of mutants with reduced antigenicity [21]. Therefore, the selection and administration of multiple vaccine antigens could reduce the risk of tumor escape through the existence and/or induction of antigen-negative variants escaping antigen-specific immune responses [22, 27], since it would be rare for tumor cells to simultaneously lose all of the multiple antigens selected for vaccination.

Collectively, our new concept of "personalized" cancer vaccine formulation, where multiple peptide antigens are selected for vaccination by the pre-existing host immunity from a list of vaccine candidates, may confer several advantages, including the possibility of bypassing both immunological diversity and tumor heterogeneity.

2.2. PPV Procedures

For PPV, a maximum of four peptides are selected based on the results of HLA typing and the pre-existing immune responses specific to each of the 31 HLA class I-restricted cytotoxic T lymphocyte (CTL) epitope peptides with minimal optimal lengths (9-mer or 10-mer): 12 peptides for HLA-A2, 14 peptides for HLA-A24, 9 peptides for HLA-A3 supertype (A3, A11, A31, or A33), and 4 peptides for HLA-A26 (Table 1). These peptides were identified mainly through the cDNA expression cloning method with tumor-infiltrating T-lymphocyte lines [25, 28-34]. The safety and

potential immunological effects of these vaccine candidates have been demonstrated in clinical studies [25, 35, 36]. It should be noted that we currently employ these 31 CTL epitopes, which are also shown to induce antigen-specific B-cell immune responses, as vaccine antigen candidates for PPV, since it has been suggested that a CTL peptide with the ability to induce antigen-specific B-cell responses could provide more effective immune responses than a CTL peptide without it [37, 38].

Although short peptide epitopes with minimal optimal lengths have been reported to bear the potential to induce immune tolerance rather than activate antigen-specific immune responses [39-41], our PPV formulation with short epitopes has been demonstrated to efficiently induce antigen-specific IFN-γ-producing CD8$^+$ T cells, but not tolerance to them, possibly because only immunogenic epitopes are selected in each patient by screening before vaccination. Although long synthetic peptides have shown excellent immune responses and promising clinical results in some clinical trials [42, 43], we do not currently use long peptides for PPV, since they may contain undesirable T-cell epitopes that activate other immune cells, such as T helper 2 cells and/or regulatory T cells [44, 45], which could negatively affect beneficial antigen-specific immune responses.

Different peptides have their own different binding affinities to the corresponding HLA molecules. Therefore, if multiple CTL-epitope peptides with different HLA-binding affinities are loaded to APCs, the individual peptides may compete with each other to bind HLA molecules on the APCs [46]. For PPV, to prevent such competition among peptides at the vaccinated sites, a maximum of 4 immunogenic peptides selected from the 31 different vaccine candidates are individually mixed with incomplete Freund's adjuvant (Montanide ISA51; Seppic, Paris, France) and subcutaneously injected at different sites, but not at a single site as a mixture. Regarding the vaccination schedule,

Table 1.   Peptide candidates used for personalized peptide vaccine (PPV).

Peptide Name	HLA Restriction	Original Protein	Position	Amino Acid Sequence
CypB-129	A2 A3sup	Cyclophilin B	129-138	KLKHYGPGWV
EGFR-800	A24	EGF-R	800-809	DYVREHKDNI
EZH2-735	A24	EZH2	735-743	KYVGIEREM
HNRPL-140	A2	HNRPL	140-148	ALVEFEDVL
HNRPL-501	A2 A26	HNRPL	501-510	NVLHFFNAPL
Lck-90	A3sup	p56 lck	90-99	ILEQSGEWWK
Lck-208	A24	p56 lck	208-216	HYTNASDGL
Lck-246	A2	p56 lck	246-254	KLVERLGAA
Lck-422	A2 A3sup	p56 lck	422-430	DVWSFGILL
Lck-449	A3sup	p56 lck	449-458	VIQNLERGYR
Lck-486	A24	p56 lck	486-494	TFDYLRSVL
Lck-488	A24	p56 lck	488-497	DYLRSVLEDF
MAP-432	A2 A26	ppMAPkkk	432-440	DLLSHAFFA
MRP3-503	A24	MRP3	503-511	LYAWEPSFL
MRP3-1293	A24	MRP3	1293-1302	NYSVRYRPGL
PAP-213	A24	PAP	213-221	LYCESVHNF
PAP-248	A3sup	PAP	248-257	GIHKQKEKSR
PSA-248	A24	PSA	248-257	HYRKWIKDTI
PSMA-624	A24	PSMA	624-632	TYSVSFDSL
PTHrP-102	A24	PTHrP	102-111	RYLTQETNKV
SART2-93	A24	SART2	93-101	DYSARWNEI
SART2-161	A24	SART2	161-169	AYDFLYNYL
SART3-109	A24 A3sup A26	SART3	109-118	VYDYNCHVDL
SART3-302	A2	SART3	302-310	LLQAEAPRL
SART3-309	A2	SART3	309-317	RLAEYQAYI
SART3-511	A3sup	SART3	511-519	WLEYYNLER
SART3-734	A3sup	SART3	734-742	QIRPIFSNR
UBE-43	A2	UBE2V	43-51	RLQEWCSVI
UBE-85	A2	UBE2V	85-93	LIADFLSGL
WHSC2-103	A2 A3sup A26	WHSC2	103-111	ASLDSDPWV
WHSC2-141	A2	WHSC2	141-149	ILGELREKV

A3sup: HLA-A3 supertype (A3, A11, A31, or A33); EGF-R: Epidermal Growth Factor Receptor; EZH2: enhancer of zeste homolog 2; HNRPL: heterogeneous nuclear ribonucleo-protein L; ppMAPkkk: partial putative mitogen-activated protein kinase kinase kinase; MRP3: multidrug resistance-associated protein 3; PAP: Prostatic acid phosphatase; PSA: prostate specific antigen; PSMA: Prostate specific membrane antigen; PTHrP : parathyroid hormone-related peptide; SART2: squamous cell carcinoma antigen recognized by T cells 2; SART3: squamous cell carcinoma antigen recognized by T cells 3; UBE2V: ubiquitin-conjugated enzyme variant Kua; WHSC2: Wolf-Hirschhorn syndrome candidate 2.

the selected peptides are administered weekly for at least the first cycle of six vaccinations, since a clear trend toward better immune responses was observed among the patients who underwent the weekly administration protocol compared to those who underwent a bi-weekly protocol in our previous clinical trials [47].

One of the noticeable characteristics of our PPV formulation is that it screens vaccine antigen candidates before vac-

cination, based on CTL-precursor frequencies and/or immunoglobulin G (IgG) titers specific to each of the candidates in pre-vaccination blood samples from each patient [25]. In the earlier stage of translational studies of PPV, pre-existing immunity was defined by the frequencies of CTL precursors in pre-vaccination peripheral blood mononuclear cells (PBMC) by detecting peptide-specific IFN-γ production by enzyme-linked immunosorbent assay (ELISA) [47-51]. However, we are currently evaluating the pre-existing im-

munity to vaccine candidates by measuring peptide-specific IgG titers in pre-vaccination plasma by the multiplex bead-based Luminex assay rather than CTL precursor frequencies, since the performance characteristics, such as the sensitivity and reproducibility, of the current T-cell assays are sometimes unsatisfactory for detecting low frequencies of antigen-specific CTL [52, 53]. In contrast to the drawbacks inherent to T-cell assays, the multiplex bead-based Luminex technology that we have developed to monitor B-cell responses allows simple, quick, and highly reproducible high-throughput screening and monitoring of IgG responses specific to a large number of peptide antigens with a tiny amount of plasma [36, 54, 55]. Indeed, the selection of vaccine antigens based on IgG titers seemed to be useful for predicting CTL boosting after vaccination in our clinical trials. The predictive power of evaluating the existence of antigen-specific CTL precursors solely by the humoral responses before vaccination could be estimated at around 50% when four peptides were chosen for PPV in each patient [56, 57].

2.3. Clinical Trials of PPV for Advanced Cancers

A series of phase I, I/II, and II clinical trials of PPV has been conducted in the past several years for various types of advanced cancer patients. Table 2 summarizes the immune and clinical responses of advanced cancer patients treated with PPV. In the following sections, we provide some detailed information on these clinical studies.

2.3.1. Castration-Resistant Prostate Cancer (CRPC)

In phase I studies of PPV for advanced HLA-A2$^+$ or HLA-A24$^+$ CRPC, we have reported increased cellular and humoral immune responses and decreased PSA levels in some patients [58, 59]. In a phase I dose-escalation study of PPV (1, 3, and 5 mg/peptide injection) for HLA-A24$^+$ CRPC, we have also demonstrated that a dose of 3 mg/peptide injection showed better cellular immune responses to vaccine peptides than either 1 or 5 mg/peptide injections, although the maximum tolerated dose (MTD) was not determined [56]. In addition, in a phase I/II study of 58 HLA-A2$^+$ or HLA-A24$^+$ CRPC patients, a combination of PPV and low-dose estramustine phosphate (EMP) showed a median survival time (MST) of 17 months (95% confidence interval (95% CI), 12 to 25 months), along with a decreased serum PSA level in the majority (76%) of patients [60]. The same study also revealed that fewer lymphocytes, negative immunological responses to vaccine antigens, and poor performance status were independent predictors of disease-related death [60].

Subsequently, we conducted a randomized phase II trial to compare PPV plus low-dose EMP with standard-dose EMP in HLA-A2$^+$ or HLA-A24$^+$ CRPC patients. The patients receiving PPV in combination with low-dose EMP showed a significantly longer progression-free survival [MST, 8.5 months vs 2.8 months; hazard ratio (HR), 0.28 (95% CI, 0.14-0.61); P = 0.0012] and overall survival [MST, undefined vs 16.1 months; HR, 0.30 (95% CI, 0.1-0.91); P = 0.0328] than those receiving standard-dose EMP alone, suggesting the efficacy of this combination therapy [61]. In another phase II study, we compared docetaxel-based chemotherapy (DBC)-resistant CRPC patients undergoing PPV (n =20) with a historical control (n = 17). MSTs from the failure of previous DBC treatments were 17.8 and 10.5 months

in patients treated with and without PPV, respectively [62]. These promising results suggested that PPV warrants further study as a novel therapy for CRPC patients, even for those with progressive disease following DBC treatment. A phase III randomized clinical trial of PPV is currently under way in DBC-resistant CRPC patients.

2.3.2. Malignant Glioma

In a phase I clinical study, we demonstrated the feasibility of PPV for HLA-A2$^+$ or HLA-A24$^+$ advanced malignant glioma patients [47]. The clinical responses of 27 patients who received more than six vaccinations were partial response (PR) in 5, stable disease (SD) in 8, and progressive disease (PD) in 8 patients, with a MST of 20.7 months. Significant levels of IgG specific to vaccine peptides were detected after vaccination in the tumor cavity or spinal fluid obtained from patients who had shown favorable clinical responses. Another phase I clinical trial in HLA-A24$^+$ patients with recurrent or progressive GBM also showed the safety and increased immune boosting of PPV with potential clinical benefits, with a MST of 10.6 months even after failure of the standard temozolomide treatment [57]. On the basis of these promising results, double-blind randomized phase III trials are under way in GBM patients resistant to the standard treatment.

2.3.3. Pancreatic Cancer and Biliary Tract Cancer

We have conducted a phase I trial of PPV in 13 HLA-A2$^+$ or HLA-A24$^+$ patients with advanced pancreatic cancer, where the patients were treated by PPV at three different doses (1, 2, or 3 mg/peptide) in combination with gemcitabin (GEM) [63]. This combination therapy was well tolerated, and 11 of 13 patients (85%) showed reduced tumor sizes and/or levels of tumor markers. Peptide-specific CTL responses were augmented at each dose level, and the increment of peptide-specific IgG antibodies was dependent on the peptide dose. These findings suggested that GEM did not inhibit the immune responses induced by PPV. Subsequently, we conducted a phase II trial of PPV in combination with GEM to evaluate the safety, clinical efficacy, and antigen-specific immune responses as a front-line therapy for 21 HLA-A2$^+$ or HLA-A24$^+$ nonresectable patients with advanced pancreatic cancer [64]. This combination therapy was also well tolerated, and the best clinical responses were PR in 7, SD in 9, and PD in 5 patients. The MST of all 21 patients was 9 months with a 1-year survival rate of 38%, which was better than that reported for GEM alone (MST of 5.7 months with a 1-year survival rate of 18%) [65]. Importantly, the MST was 15 months in patients who showed immunological responses to vaccine peptides.

We also conducted a phase II clinical trial of PPV in 25 HLA-A2$^+$ or HLA-A24$^+$ chemotherapy-resistant patients with advanced biliary tract cancer [66]. When two to four vaccine peptides selected by pre-existing immunity were administered to the patients in this study, humoral and/or T-cell responses specific to the vaccine antigens were substantially induced in a subset of the patients without severe adverse events. Greater numbers of selected and vaccinated peptides were significantly favorable factors for overall survival (HR = 0.258, 95% CI = 0.098-0.682, P = 0.006) in this study (Table 3).

Table 2.   List of clinical trials of personalized peptide vaccines (PPV) for advanced cancer.

Organ	Disease condition	Phase of trial	HLA restriction	Combined treatment	No. of Patients	Clinical response	MST (months)	Toxicities (Grade 3/4)	Humoral response (%)	Cellular response (%)	Reference
Prostate (CRPC)	Advanced	I	A24	-	10	SD 50%	NA	-	60	40	[58]
Prostate (CRPC)	Advanced	I	A24	EMP	13	PR 63%	24	G3, 5%	91	55	[114]
Prostate (CRPC)	Advanced	I	A2	-	10	SD 30%	22	-	70	40	[59]
Prostate (CRPC)	Advanced	I/II	A24	EMP	16	PR 43%	17	-	50	71	[115]
Prostate (CRPC)	Advanced	I/II	A2/A24	EMP	58	PR 24%	17	G3, 7%	88	78	[60]
Prostate (CRPC)	Advanced	I	A24	EMP	15	PR 13%	24	-	47	67	[56]
Prostate (CRPC)	Advanced	II (Randomized)	A2/A24	EMP	57	8.5M vs 2.8M (PFS)	22.4M vs 16.1M	-	64	50	[61]
Prostate (CRPC)	Advanced	II	A2/A24/ A3sup/A26	-	42	PR 12%	17.8	-	44	34	[62]
Prostate	Localized	II	A24	-	10	PR 20%	NA	-	80	80	[116]
Brain	Advanced malignant glioma	I	A2/A24	-	21	PR 24%, SD 38%	NA	-	40 - 64	50 - 82	[47]
Brain	Advanced GBM	I	A24	-	12	PR 17%, SD 42%	10.6	-	17	75	[57]
Pancreas	Advanced	I	A2/A24	GEM	13	PR 15%, SD 54%	7.6	-	69	69	[63]
Pancreas	Advanced	II	A2/A24	GEM	21	PR 33%, SD 43%	9	-	72	78	[64]
Biliary tract	Advanced	II	A2/A24/ A3sup/A26	Chemotherapy	25	SD 32%	NA	G3, 4%	35	47	[66]
Stomach	Advanced	I	A2/A24	-	13	SD 45%	NA	-	80	50	[67]
Stomach Colorectal	Advanced	I/II	A2/A24	S-1	11	SD 36%	NA	G3, 18%	81	63	[69]
Colorectal	Advanced	I	A24	-	10	PR 10%	NA	-	70	50	[68]
Colorectal	Metastatic	I	A2/A24	UFT UZEL	13	SD 43%	19.6	G3, 7.7%	69	85	[70]
Lung	Advanced	I	A24	-	10	SD 80%	15.2	-	40	40	[50]
Lung	Advanced (NSCLC)	II	A2/A24 A3sup/A26	Chemotherapy	41	SD 56%	10.1	G3, 7%	49	34	[71]
Lung	Advanced (SCLC)	II	A2/A24 A3sup/A26	Chemotherapy	10	SD 20%	6.2	G3, 4%	83	83	[72]

(Table 2) contd....

Organ	Disease condition	Phase of trial	HLA restriction	Combined treatment	No. of Patients	Clinical response	MST (months)	Toxicities (Grade 3/4)	Humoral response (%)	Cellular response (%)	Reference
Urothelial	Advanced	I	A2/A24	-	10	CR 10%, PR 10%	24	-	80	80	[73]
Kidney	Metastatic	I	A2/A24	-	10	SD 60%	23	-	80	5	[74]
Uterine, Ovary	Recurrent	I	A2/A24	-	14	SD 36%	NA	G3, 8%	86	86	[49]
Skin	Malignant melanoma	I	A2/A24	-	7	SD 43%	NA	-	57	86	[51]

CRPC: castration-resistant prostate cancer; GBM: glioblastoma multiforme; SCLC: small cell lung cancer; NSCLC: non-small cell lung cancer; A3sup: HLA-A3 supertype (A3, A11, A31, or A33); EMP: estramustine phosphate; GEM: gemcitabine; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; PFS: progression-free survival; MST: median survival time; NA: not assessed; M: months.

Table 3.   Biomarkers for personalized peptide vaccines (PPV) for advanced cancer.

Type of cancer	Factor	Statistical analysis (HR, 95% CI, P value)	Reference
Miscellaneous (n = 500)[a]	Performance status (1, 2, 3 vs 0)	HR = 2.295; 95% CI, 1.653 - 3.188; $P < 0.0001$	[36]
	Lymphocyte counts (<1500μL vs > 1500μL)	HR = 1.472; 95% CI, 1.099 - 1.972, $P = 0.0095$	
	IgG responses to antigens after vaccination (no vs yes)	HR = 1.455; 95% CI, 1.087 - 1.948, $P = 0.0116$	
Prostate (CRPC, n = 40)	IL-6 MDSC	(Not determined) (Not determined)	[81]
Non-small lung cell cancer (n =41)[a]	C-reactive protein (CRP)	HR = 10.115, 95% CI = 2.447 – 41.806, $P = 0.001$	[71]
Biliary tract (n = 25)[a]	IL-6	HR = 1.123, 95% CI = 1.008 -1.252, $P = 0.035$	[66]
	Albumin	HR = 0.158; 95% CI, 0.029 - 0.860; $P = 0.033$	
	Numbers of vaccine peptides	HR = 0.258, 95% CI = 0.098-0.682, $P = 0.006$	

[a]Potential biomarkers for PPV were determined by multivariate Cox regression analyses. ; HR: hazard ratio; CI: confidence interval; CRPC: castration-resistant prostate cancer; MDSC: myeloid-derived suppressor cells.

2.3.4. Gastric Cancer and Colorectal Cancer

In a phase I clinical trial of PPV in 13 HLA-A2$^+$ or HLA-A24$^+$ patients with advanced gastric cancer (9 nonscirrhous and 4 scirrhous), prolonged survival was observed in patients who showed cellular and humoral immune responses to the vaccine peptides in the post-vaccination blood samples, including all 4 patients with the scirrhous type [67]. In addition, a phase I clinical trial of PPV in 10 HLA-A24$^+$ patients with advanced colorectal cancer showed one PR and one SD, each continuing for more than 6 months [68].

In a phase I/II clinical trial of PPV in combination with three different doses (20, 40, or 80 mg/m²/day) of oral administration of a 5-fluorouracil derivative, S-1, for 11 HLA-A2$^+$ or HLA-A24$^+$ advanced gastric or colorectal cancer patients [69], the combined administration of the standard dose (80 mg/m²/day) of S-1 did not inhibit immunological re-

sponses to vaccine antigens, but instead maintained or augmented them. In another phase I clinical trial for 13 HLA-A2$^+$ or HLA-A24$^+$ metastatic colorectal cancer patients [70], the combined treatment of PPV and the oral administration of a 5-fluorouracil derivative, UFT, and calcium folinate, UZEL, proved to be safe and to induce good antigen-specific immune responses. In this trial, IgG responses to the vaccine peptides correlated well with overall survival. These encouraging results suggest that combined treatment with PPV and standard chemotherapeutic agents might be promising for advanced gastric and colorectal cancers.

2.3.5. Lung Cancer

The prognosis of advanced lung cancer patients remains very poor, with a MST of around 6-10 months. Phase I and II studies of PPV in a small number of patients with refractory NSCLC demonstrated that PPV was safe and well tolerated,

with no major adverse effects, and that PPV treatment resulted in longer survival (MST of 10.1 or 15.2 months) [50, 71]. A clinical study in 10 advanced small cell lung cancer (SCLC) also showed the safety and feasibility of PPV [72].

2.3.6. Urothelial Cancer

A phase I clinical trial of PPV was conducted in 10 HLA-A2$^+$ or HLA-A24$^+$ refractory urothelial cancer patients [73]. In this study, some patients treated by PPV showed clear clinical responses as evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria with boosted immune responses: CR in 1, PR in 1, and SD in 2 patients. These 4 responders showed better progression-free survival (MST, 21 months) and overall survival (MST, 24 months), suggesting the potential clinical efficacy of PPV for advanced urothelial cancer.

2.3.7. Other Cancers

We also conducted phase I clinical trials for other advanced cancers, including metastatic renal cell carcinoma (RCC) [74], gynecologic cancers [49], and malignant melanoma [51]. All of these studies demonstrated that PPV was safe and well tolerated with no major adverse effects, and that good immune responses to vaccine antigens were induced in many of the patients after PPV. Further clinical trials would be required to clearly prove the clinical benefits of PPV in these cancers.

2.4. Biomarkers for PPV (Table 3)

Recent clinical trials of cancer immunotherapies, including peptide-based cancer vaccines, have demonstrated that only a subset of patients show clinical benefits. Furthermore, unexpectedly, some large clinical trials in the past several years have demonstrated that cancer vaccines might sometimes show worse clinical outcomes [75, 76]. It would thus be important to identify predictive biomarkers that could accurately assess anti-tumor immune responses and predict patient prognosis following the administration of cancer vaccines. In some clinical trials, several post-vaccination biomarkers, including CTL responses, Th1 responses, delayed-type hypersensitivity (DTH), and autoimmunity, have been reported to be associated with clinical responses.[77-80]. However, there are currently no validated biomarkers for cancer vaccines in widespread use.

To identify biomarkers for PPV, we statistically reviewed 500 advanced cancer patients undergoing PPV from October 2000 to October 2008 [36]. Both lymphocyte counts before vaccination ($P = 0.0095$) and increased IgG response ($P = 0.0116$) to the vaccine peptides after vaccination, along with performance status ($P < 0.0001$), were well correlated with overall survival. In CRPC patients treated with PPV (n = 40), a comprehensive study of soluble factors assessed by multiplexed bead array in plasma and gene expression profiles by DNA microarray in PBMC demonstrated that higher IL-6 level and granulocytic myeloid-derived suppressor cells (MDSC) in the peripheral blood before vaccination were closely related to poorer prognosis in the vaccinated patients [81]. By multivariate Cox regression analyses in patients with refractory NSCLC (n = 41), higher C-reactive protein (CRP) level before vaccination was a significant predictor of

unfavorable overall survival (HR = 10.115, 95% CI = 2.447 – 41.806, $P = 0.001$) [71]. In addition, in refractory biliary tract cancer patients (n = 25), multivariate Cox regression analyses showed that higher IL-6 and lower albumin levels before vaccination were significantly unfavorable factors for overall survival [HR = 1.123, 95% CI = 1.008 - 1.252, $P = 0.035$; HR = 0.158, 95% CI = 0.029 - 0.860, $P = 0.033$; respectively] [66].

Collectively, these findings suggested that less inflammation may contribute to better responses to PPV, indicating that the evaluation of inflammatory factors before vaccination could be useful for selecting cancer patients who are appropriate for PPV (Table 3). An early phase clinical trial is under way to reveal whether or not the blockage of IL-6-mediated inflammatory signaling with a humanized anti-IL-6 receptor monoclonal antibody, tocilizumab, would be beneficial for enhancing the immune and/or clinical responses after PPV in advanced cancer patients who show higher plasma IL-6 levels [82, 83].

3. OTHER NEW TYPES OF PEPTIDE VACCINES

Recent early phase clinical trials have also demonstrated significant advances in other types of therapeutic peptide-based vaccines [19, 20]. Several new types of peptide-based vaccines are reviewed in this section (Fig. 1).

3.1. Multi-Peptide Vaccine Consisting of CTL and Helper T-Cell Epitopes

Numerous helper T-cell epitopes have been identified from TAA. Since helper T cells are known to play crucial roles in the efficient induction of CTL responses, cancer vaccines, which consist of both HLA class II-restricted helper epitopes recognized by CD4 T cells and class I-restricted CTL epitopes recognized by CD8 T cells, have been developed and clinically tested [84-89]. For example, Kuball et al. conducted a phase I study of a multi-peptide vaccine consisting of multiple CTL epitopes from Wilms tumor gene-1 (WT-1), proteinase 3 (Pr3) and mucin 1 (MUC1), and MUC1-helper epitope or pan HLA-DR epitope (PADRE) [84]. Each peptide was formulated separately and injected at a different site. In this study, an increase in PADRE-specific CD4 T cells, which appeared unable to produce IL2, was observed after vaccination, and regulatory T cells were increased, suggesting that helper epitope peptides have the potential to induce not only helper T cells but also regulatory T cells. Krug et al. tested the safety and immunogenicity of a WT1 vaccine comprised of four class I and class II-restricted peptides in patients with malignant pleural mesothelioma or NSCLC expressing WT1 [85]. They showed that this multivalent WT1 peptide vaccine induced both CD4 and CD8 T-cell responses in a high proportion of patients with minimal toxicity.

3.2. Multi-Peptide Cocktail Vaccine

If each of multiple peptides are formulated separately and injected at a separate site, the number of peptides employed for vaccination might be limited. One strategy for overcoming this limitation is to generate multi-peptide cocktail vaccines, since one preparation could contain more than 10 different peptides. Although the issue of competition between

individual peptides to bind to HLA molecules on the APCs still remains [46], different types of multi-peptide cocktail vaccines have been developed; vaccines consisting of CTL epitope peptides alone [90, 91] or those of both CTL epitope and helper epitope peptides [86-89].

Barve *et al.* conducted a phase I/II study of a multi-peptide cocktail vaccine, IDM-2101, consisting of nine CTL epitope peptides and the PADRE helper epitope peptide with Montanide ISA51 in patients with metastatic non-small cell lung cancer [86]. No significant adverse events were noted except for low-grade erythema and pain at the injection site. One-year survival in the treated patients was 60%, with a median overall survival of 17.3 months. One complete response (CR) patient was observed in the total of 63 patients. Slingluff *et al.* conducted a multicenter randomized trial to examine the immunogenicity of a multi-peptide cocktail vaccine containing 12 melanoma-associated HLA class I-restricted peptides (12MP) for CD8$^+$ T cells and tetanus peptide or a mixture of six melanoma-associated helper peptides (6MHP) for CD4$^+$ T cells in the presence or absence of cyclophosphamide pretreatment in 167 patients with resected stage IIB to IV melanoma [87]. However, the combination of 6MHP with 12MP paradoxically reduced the circulating CD8$^+$ T-cell response, and cyclophosphamide pretreatment had no measurable effect on CD8$^+$ or CD4$^+$ responses. Clinical outcome was not improved by adding melanoma-associated helper peptides or by adding cyclophosphamide.

Rammensee and his colleagues also reported a phase I/II trial of a multi-peptide cocktail vaccine, which consisted of 13 synthetic peptides (11 HLA-A*0201-restricted CTL epitopes and 2 helper epitopes derived from prostate tumor antigens) for 19 HLA-A2$^+$ hormone-sensitive prostate cancer patients with biochemical recurrence after primary surgical treatment [88]. The vaccine was well tolerated, and stabilized or slowed down PSA progress in 4 of the 19 patients. The same group also developed another cocktail vaccine, IMA901, which consisted of nine HLA-A*0201-restricted CTL epitopes and one helper epitope from renal cell cancer antigens with hepatitis B virus epitope as a marker peptide, for advanced renal cell cancer [89]. In a randomized phase II trial with a single dose of cyclophosphamide, the number of regulatory T cells was reduced, and immune responses to the vaccine peptides were associated with longer overall survival. A randomized phase III study to determine the clinical benefit of IMA901 is ongoing.

3.3. Hybrid Peptide Vaccine

Peptides used in most clinical trials for peptide-based vaccines possess native amino acid sequences with or without slight modification in anchor amino acids to increase their binding capability to HLA molecules. However, hybrid-type peptide vaccines, which use a new artificial peptide fusing two or more peptides, have been devised. For example, the Ii-Key/HER-2/neu hybrid peptide vaccine, a fusion peptide made up of the Ii-Key 4-mer peptide and HER-2/neu (776-790) helper epitope peptide, has been reported [92, 93]. The Ii/Key 4-mer peptide is the shortest active sequence of the Ii protein, which catalyzes direct charging of MHC class II epitopes to the peptide-binding groove, circumventing the need for intracellular epitope processing [94]. Phase I studies

of the Ii-Key/HER-2/neu hybrid peptide vaccine in patients with prostate cancer showed that this vaccine is safe and can induce HER-2/neu-specific cellular immune responses in vaccinated patients [93]. In addition, significant decreases in circulating regulatory T-cell frequencies, plasma HER2/neu, and serum TGF-beta levels were observed.

Nishimura *et al.* reported an artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP) of MAGE-A4 cancer antigen [95]. In the first case report, a patient with pulmonary metastasis of colon cancer was vaccinated with MAGE-A4-H/K-HELP in combination with OK432 and Montanide ISA51. There were no severe side effects except for a skin reaction at the injection site. Vaccination with MAGE-A4-H/K-HELP induced MAGE-A4-specific Th1 and Tc1 immune responses and the production of MAGE-A4-specific complement-fixing IgG antibodies. Tumor growth and tumor markers were significantly decreased in this patient.

3.4. Long Peptide Vaccine

The classical types of peptide vaccines have consisted of short epitope peptides with minimal optimal lengths, which are recognized by CTLs or helper T cells in an HLA class I- or class II-restricted manner, respectively. However, direct binding of short peptides to nonspecific cells without a co-stimulatory capacity has been reported to bear the potential to induce tolerance to antigen-specific T cells rather than to induce their activation in some mouse models [39-41]. Therefore, a novel approach using synthetic long peptides, which need to be taken up by professional APCs and processed for presentation by HLA class I and/or class II molecules, has been developed for cancer vaccination, although the efficiency and mechanisms of presentation of exogenous long peptides in human HLA class I remain to be fully elucidated [96]. Synthetic long peptides may contain not only HLA class I-restricted but also HLA class II-restricted epitopes, which can activate helper T cells important for the efficient induction of antigen-specific CTL responses.

Several clinical studies using a pool of multiple synthetic long peptides have been reported, since a mixture of multiple synthetic long peptides is likely to contain multiple HLA class I-restricted and class II-restricted T-cell epitopes, which could be applicable to any patients irrespective of their HLA types [42-45, 97-100]. Melief and his colleagues showed that a vaccine composed of a synthetic long peptide pool derived from high-risk-type human papillomavirus (HPV)-16 E6/E7 oncoproteins successfully induced HPV-specific immune responses [42, 43]. They conducted a phase I study of HPV16 E6 and E7 overlapping long peptides in end-stage cervical cancer patients [42]. Cocktails of nine E6 peptides and/or four E7 peptides covering the entire sequences of E6 and E7 proteins showed a strong and broad T-cell response dominated by immunity against E6 after four subcutaneous administrations with Montanide ISA51 at 3-week intervals. Subsequently, they conducted a phase II study of the same vaccine in patients with HPV-positive grade 3 vulvar intraepithelial neoplasia, which is a chronic disorder caused by HPV [43]. At 3 months after the last vaccination, 12 of 20 patients (60%) had clinical responses and reported relief of symptoms. Five women had complete regression of the lesions. At 12 months of follow-up, 15 of 19

patients (79%) had clinical responses, with a complete response in 9 of 19 patients (47%).

The same group also reported a synthetic long peptide vaccine targeted for p53. This p53 synthetic long peptide vaccine (p53-SLP) consisted of 10 synthetic 25-mer to 30-mer long overlapping peptides, spanning amino acids 70–248 of the wild-type p53 protein. In a phase I/II trial of the p53-SLP vaccine in 10 patients with metastatic colorectal cancer, p53-specific T-cell responses were induced in 9 of 10 patients as measured by IFN-γ enzyme-linked immunospot (ELISPOT), proliferation, and cytokine bead arrays [97]. Subsequently, a phase II study of the same vaccine in 20 ovarian cancer patients with recurrent elevation of CA-125 showed that SD, as determined by CA-125 levels and CT scans, was observed in 2 out of 20 patients (10%) as the best clinical response, but no relationship was found between the clinical response and vaccine-induced immunity [44]. IFN-γ–producing p53-specific responses were induced in CD4 T cells, but not in CD8 T cells, in all patients who received four immunizations. The absence of p53-specific CD8 T-cell responses might be attributable to the dominant production of Th2 cytokines by CD4 T cells, which have inhibitory effects on CTL induction. Nevertheless, the combined use of p53-SLP vaccine and a low dose of cyclophosphamide or IFN-α has recently been reported to efficiently induce more IFN-γ–producing p53-specific T cells, suggesting that these combinations may potentiate the immunogenicity of the p53-SLP vaccine [98, 99].

Kakimi *et al.* also conducted a phase I trial of an NY-ESO-1 synthetic long peptide vaccine. A 20-mer peptide spanning from amino acid 91 to 110 of NY-ESO-1, called NY-ESO-1f, which includes multiple epitopes recognized by antibodies and CD4 and CD8 T cells, was administered along with OK-432 and Montanide ISA51 to patients with advanced cancers [100]. Both antigen-specific CD4 and CD8 T-cell responses, as well as antibody responses, were increased in 9 of 10 patients.

3.5. Novel Approach for Targeting Peptides to Professional APCs

The goal of cancer immunotherapy is to induce and amplify functional antigen-specific immune responses in order to develop long-lasting immunological memory specific to tumor cells [101, 102]. However, one hurdle to the use of peptide-based vaccines is that the uptake and/or presentation of vaccine peptides by nonspecific cells, but not by professional APCs, leads to CTL anergy through insufficient stimulation [103]. For efficient priming and activation of antigen-specific CTL through vaccination, sufficient amounts of antigens should be presented to T cells by functionally activated, professional APCs for sufficient periods of time [104-107]. In this respect, a novel delivery system for peptide vaccines remains to be developed.

For example, nanotechnology-based antigen delivery has been developing as a vaccine strategy due to its dose-sparing and prolonged antigen presentation features [108, 109]. In particular, polymeric nanoparticles (NP) have attracted increasing attention as carriers of therapeutic immunogens [110]. Antigen peptides encapsulated in polymeric NP are shown to be directly and specifically delivered to profes-

sional APCs via phagocytosis without proteolytic degradation, and efficiently cross-presented to induce strong T-cell immunity, whereas those in solution that are internalized by APCs via macropinocytosis are reported to be poorly presented as peptides in complex with MHC class I molecules on cell surfaces [111, 112]. Indeed, we have demonstrated the feasibility of NP consisting of a biodegradable, biocompatible copolymer, poly(D,L-lactide-co-glycolide) (PLGA) carrying antigenic peptides and a toll-like receptor 4 agonist, monophosphoryl lipid A, to efficiently induce CTL responses against TAA in murine tumor models [113]. To increase the efficacy of peptide-based vaccines, such a novel antigen delivery system remains to be developed and clinically examined.

CONCLUSIONS

In the field of cancer immunology and immunotherapy, excitement and enthusiasm have risen around the latest approvals of immunotherapy-based treatments in various cancer types. However, several issues remain to be addressed in order to achieve further development of cancer vaccines. In particular, in view of the complexity and diversity of tumor cell characteristics and host immune cell repertoires, the selection of vaccine peptides appropriate for individual patients based on the pre-existing host immunity before vaccination could be critical for the efficient induction of beneficial anti-tumor responses in cancer patients. In a series of clinical trials, we have demonstrated promising results of PPV as a new treatment modality for patients with various types of advanced cancer. Further randomized phase III clinical trials are essential to validate the clinical benefits of PPV. Moreover, novel biomarkers for selecting patients who would benefit most from PPV remain to be addressed.

CONFLICT OF INTEREST

Akira Yamada is an Executive Officer for Green Peptide Company, Ltd. Kyogo Itoh received a research grant from the Green Peptide Company, Ltd. and owns stock in the Green Peptide Company, Ltd.

REFERENCES

[1]   Finn, O.J. Cancer immunology. *N. Engl. J. Med.*, **2008**, *358*(25), 2704-2715.

[2]   Rosenberg, S.A. Cell transfer immunotherapy for metastatic solid cancer-what clinicians need to know. *Nat. Rev. Clin. Oncol.*, **2011**, *8*(10), 577-585.

[3]   Mellman, I.; Coukos, G.; Dranoff, G. Cancer immunotherapy comes of age. *Nature*, **2011**, *480*(7378), 480-489.

[4]   Schlom, J. Therapeutic cancer vaccines: current status and moving forward. *J. Natl. Cancer Inst.*, **2012**, *104*(8), 599-613.

[5]   Itoh, K.; Yamada, A.; Mine, T.; Noguchi, M. Recent advances in cancer vaccines: an overview. *Jpn. J. Clin. Oncol.*, **2009**, *39*(2), 73-80.

[6]   Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B.; Xu, Y.; Frohlich, M.W.; Schellhammer, P.F. IMPACT Study

Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N. Engl. J. Med.*, 2010, *363*(5), 411-422.

[7]   Hodi, F.S.; O'Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; Akerley, W.; van den Eertwegh, A.J.; Lutzky, J.; Lorigan, P.; Vaubel, J.M.; Linette, G.P.; Hogg, D.; Ottensmeier, C.H.; Lebbé, C.; Peschel, C.; Quirt, I.; Clark, J.I.; Wolchok, J.D.; Weber, J.S.; Tian, J.; Yellin, M.J.; Nichol, G.M.; Hoos, A.; Urba, W.J. Improved survival with ipilimumab in patients with metastatic melanoma. *N. Engl. J. Med.*, 2010, *363*(8), 711-723.

[8]   Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; Leming, P.D.; Spigel, D.R.; Antonia, S.J.; Horn, L.; Drake, C.G.; Pardoll, D.M.; Chen, L.; Sharfman, W.H.; Anders, R.A.; Taube, J.M.; McMiller, T.L.; Xu, H.; Korman, A.J.; Jure-Kunkel, M.; Agrawal, S.; McDonald, D.; Kollia, G.D.; Gupta, A.; Wigginton, J.M.; Sznol, M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N. Engl. J. Med.*, 2012, *366*(26), 2443-2454.

[9]   Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; Pitot, H.C.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton, K.; Chen, S.; Salay, T.M.; Alaparthy, S.; Grosso, J.F.; Korman, A.J.; Parker, S.M.; Agrawal, S.; Goldberg, S.M.; Pardoll, D.M.; Gupta, A.; Wigginton, J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N. Engl. J. Med.*, 2012, *366*(26), 2455-2465.

[10]   van der Bruggen, P.; Traversari, C.; Chomez, P.; Lurquin, C.; De Plaen, E.; Van den Eynde, B.; Knuth, A.; Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. *Science*, 1991, *254*(5038), 1643-1647.

[11]   Türeci, O.; Sahin, U.; Schobert, I.; Koslowski, M.; Scmitt, H.; Schild, H.J.; Stenner, F.; Seitz, G.; Rammensee, H.G.; Pfreundschuh, M. The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. *Cancer Res.*, 1996, *56*(20), 4766-4772.

[12]   Cheever, M.A.; Allison, J.P.; Ferris, A.S.; Finn, O.J.; Hastings, B.M.; Hecht, T.T.; Mellman, I.; Prindiville, S.A.; Viner, J.L.; Weiner, L.M.; Matrisian, L.M. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. *Clin. Cancer Res.*, 2009, *15*(17), 5323-5337.

[13]   Singh-Jasuja, H.; Emmerich, N.P.; Rammensee, H.G. The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy. *Cancer Immunol. Immunother.*, 2004, *53*(3), 187-195.

[14]   Kessler, J.H.; Melief, C.J. Identification of T-cell epitopes for cancer immunotherapy. *Leukemia*, 2007, *21*(9), 1859-1874.

[15]   Hu, X.; Chakraborty, N.G.; Sporn, J.R.; Kurtzman, S.H.; Ergin, M.T.; Mukherji, B. Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine. *Cancer Res.*, 1996, *56*(11), 2479-2483.

[16]   Rosenberg, S.A.; Yang, J.C.; Restifo, N.P. Cancer immunotherapy: moving beyond current vaccines. *Nat. Med.*, 2004, *10*(9), 909-915.

[17]   Purcell, A.W.; McCluskey, J.; Rossjohn, J. More than one reason to rethink the use of peptides in vaccine design. *Nat. Rev. Drug Discov.*, 2007, *6*(5), 404-414.

[18]   Schwartzentruber, D.J.; Lawson, D.H.; Richards, J.M.; Conry, R.M.; Miller, D.M.; Treisman, J.; Gailani, F.; Riley, L.; Conlon, K.; Pockaj, B.; Kendra, K.L.; White, R.L.; Gonzalez, R.; Kuzel, T.M.; Curti, B.; Leming, P.D.; Whitman, E.D.; Balkissoon, J.; Reintgen, D.S.; Kaufman, H.; Marincola, F.M.; Merino, M.J.; Rosenberg, S.A.; Choyke, P.; Vena, D.; Hwu, P. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. *N. Engl. J. Med.*, 2011, *364*(22), 2119-2127.

[19]   Yamada, A.; Sasada, T.; Noguchi, M.; Itoh, K. Next-generation peptide vaccines for advanced cancer. *Cancer Sci.*, 2013, *104*(1), 15-21.

[20]   Perez, S.A.; von Hofe, E.; Kallinteris, N.L.; Gritzapis, A.D.; Peoples, G.E.; Papamichail, M.; Baxevanis, C.N. A new era in anticancer peptide vaccines. *Cancer*, 2010, *116*(9), 2071-2080.

[21]   Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. *Science*, 2011, *331*(6024), 1565-1570.

[22]   Bei, R.; Scardino, A. TAA polyepitope DNA-based vaccines: a potential tool for cancer therapy. *J. Biomed. Biotechnol.*, 2010, *2010*, 102758.

[23]   Yewdell, J.W.; Bennink, J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. *Annu. Rev. Immunol.*, 1999, *17*, 51-88.

[24]   Chen, W.; McCluskey, J. Immunodominance and immunodomination: critical factors in developing effective CD8+ T-cell-based cancer vaccines. *Adv. Cancer Res.*, 2006, *95*, 203-247.

[25]   Itoh, K.; Yamada, A. Personalized peptide vaccines: a new therapeutic modality for cancer. *Cancer Sci.*, 2006, *97*(10), 970-976.

[26]   Mochizuki, K.; Sato, Y.; Tsuda, N.; Shomura, H.; Sakamoto, M.; Matsuura, K.; Ushijima, K.; Maeda, Y.; Katagiri, K.; Yamada, A.; Todo, S.; Kamura, T.; Harada, M.; Itoh, K. Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. *Int. J. Oncol.*, 2004, *25*(1), 121-131.

[27]   Pilla, L.; Rivoltini, L.; Patuzzo, R.; Marrari, A.; Valdagni, R.; Parmiani, G. Multipeptide vaccination in cancer patients. *Expert Opin. Biol. Ther.*, 2009, *9*(8), 1043-1055.

[28]   Nakao, M.; Shichijo, S.; Imaizumi, T.; Inoue, Y.; Matsunaga, K.; Yamada, A.; Kikuchi, M.; Tsuda, N.; Ohta, K.; Takamori, S.; Yamana, H.; Fujita, H.; Itoh, K. Identification of a gene coding for a new squamous cell carcinoma antigen recognized by the CTL. *J. Immunol.*, 2000, *164*(5), 2565-2574.

[29]   Shichijo, S.; Nakao, M.; Imai, Y.; Takasu, H.; Kawamoto, M.; Niiya, F.; Yang, D.; Toh, Y.; Yamana, H.; Itoh, K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. *J. Exp. Med.*, 1998, *187*(3), 277-288.

[30]   Harashima, N.; Tanaka, K.; Sasatomi, T.; Shimizu, K.; Miyagi, Y.; Yamada, A.; Tamura, M.; Yamana, H.; Itoh, K.; Shichijo, S. Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases. *Eur. J. Immunol.*, 2001, *31*(2), 323-332.

[31]   Yamada, A.; Kawano, K.; Koga, M.; Matsumoto, T.;. Itoh, K. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. *Cancer Res.*, 2001, *61*(17), 6459-6466.

[32]   Harada, M.; Kobayashi, K.; Matsueda, S.; Nakagawa, M.; Noguchi, M.; Itoh, K. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients. *Prostate*, 2003, *57*(2), 152-159.

[33]   Inoue, Y.; Takaue, Y.; Takei, M.; Kato, K.; Kanai, S.; Harada, Y.; Tobisu, K.; Noguchi, M.; Kakizoe, T.; Itoh, K.; Wakasugi, H. Induction of tumor specific cytotoxic T lymphocytes in prostate cancer using prostatic acid phosphatase derived HLA-A2402 binding peptide. *J. Urol.*, 2001, *166*(4), 1508-1513.

[34]   Kobayashi, K.; Noguchi, M.; Itoh, K.; Harada, M. Identification of a prostate-specific membrane antigen-derived peptide capable of eliciting both cellular and humoral immune responses in HLA-A24+ prostate cancer patients. *Cancer Sci.*, 2003, *94*(7), 622-627.

[35]   Yoshida, K.; Noguchi, M.; Mine, T.; Komatsu, N.; Yutani, S.; Ueno, T.; Yanagimoto, H.; Kawano, K.; Itoh, K.; Yamada, A. Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases. *Oncol. Rep.*, 2011, *25*(1), 57-62.

[36]   Noguchi, M.; Mine, T.; Komatsu, N.; Suekane, S.; Moriya, F.; Matsuoka, K.; Yutani, S.; Shichijo, S.; Yamada, A.; Toh, U.; Kawano, K.; Azuma, K.; Uemura, H.; Okuno, K.; Matsumoto, K.; Yanagimoto, H.; Yamanaka, R.; Oka, M.; Todo, S.; Sasada, T.; Itoh, K. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. *Cancer Biol. Ther.*, 2011, *10*(12), 1266-1279.

[37]   Avogadri, F.; Merghoub, T.; Maughan, M.F.; Hirschhorn-Cymerman, D.; Morris, J.; Ritter, E.; Olmsted, R.; Houghton, A.N.; Wolchok, J.D. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. *PLoS One*, 2010, *5*(9), e12670.

[38]   Hong, S.; Qian, J.; Li, H.; Yang, J.; Lu, Y.; Zheng, Y.; Yi, Q. CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. *Cancer Immunol. Immunother.*, 2012, *61*(4), 561-571.

[39]   Melief, C.J.; van der Burg, S.H. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. *Nat. Rev. Cancer,* **2008,** *8*(5), 351-360.

[40]   Bijker, M.S.; van den Eeden, S.J.; Franken, K.L.; Melief, C.J.; Offringa, R.; van der Burg, S.H. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. *J. Immunol.,* **2007,** *179*(8), 5033-5040.

[41]   Toes, R.E.; Offringa, R.; Blom, R.J.; Melief, C.J.; Kast, W.M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. *Proc. Natl. Acad. Sci. USA,* **1996,** *93*(15), 7855-7860.

[42]   Kenter, G.G.; Welters, M.J.; Valentijn, A.R.; Lowik, M.J.; Berends-van der Meer, D.M.; Vloon, A.P.; Drijfhout, J.W.; Wafelman, A.R.; Oostendorp, J.; Fleuren, G.J.; Offringa, R.; van der Burg, S.H.; Melief, C.J. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. *Clin. Cancer Res.,* **2008,** *14*(1), 169-177.

[43]   Kenter, G.G.; Welters, M.J.; Valentijn, A.R.; Lowik, M.J.; Berends-van der Meer, D.M.; Vloon, A.P.; Essahsah, F.; Fathers, L.M.; Offringa, R.; Drijfhout, J.W.; Wafelman, A.R.; Oostendorp, J.; Fleuren, G.J.; van der Burg, S.H.; Melief, C.J. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. *N. Engl. J. Med.,* **2009,** *361*(19), 1838-1847.

[44]   Leffers, N.; Lambeck, A.J.; Gooden, M.J.; Hoogeboom, B.N.; Wolf, R.; Hamming, I.E.; Hepkema, B.G.; Willemse, P.H.; Molmans, B.H.; Hollema, H.; Drijfhout, J.W.; Sluiter, W.J.; Valentijn, A.R.; Fathers, L.M.; Oostendorp, J.; van der Zee, A.G.; Melief, C.J.; van der Burg, S.H.; Daemen, T.; Nijman, H.W. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. *Int. J. Cancer,* **2009,** *125*(9), 2104-2113.

[45]   Welters, M.J.; Kenter, G.G.; Piersma, S.J.; Vloon, A.P.; Löwik, M.J.; Berends-van der Meer, D.M.; Drijfhout, J.W.; Valentijn, A.R.; Wafelman, A.R.; Oostendorp, J.; Fleuren, G.J.; Offringa, R.; Melief, C.J.; van der Burg, S.H. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. *Clin. Cancer Res.,* **2008,** *14*(1), 178-187.

[46]   Rosenberg, S.A.; Sherry, R.M.; Morton, K.E.; Yang, J.C.; Topalian, S.L.; Royal, R.E.; Kammula, U.S.; Restifo, N.P.; Hughes, M.S.; Schwarz, S.L.; Ngo, L.T.; Mavroukakis, S.A.; White, D.E. Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. *J. Immunother.,* **2006,** *29*(2), 224-231.

[47]   Yajima, N.; Yamanaka, R.; Mine, T.; Tsuchiya, N.; Homma, J.; Sano, M.; Kuramoto, T.; Obata, Y.; Komatsu, N.; Arima, Y.; Yamada, A.; Shigemori, M.; Itoh, K.; Tanaka, R. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. *Clin. Cancer Res.,* **2005,** *11*(16), 5900-5911.

[48]   Hida, N.; Maeda, Y.; Katagiri, K.; Takasu, H.; Harada, M.; Itoh, K. A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. *Cancer Immunol. Immunother.,* **2002,** *51*(4), 219-228.

[49]   Tsuda, N.; Mochizuki, K.; Harada, M.; Sukehiro, A.; Kawano, K.; Yamada, A.; Ushijima, K.; Sugiyama, T.; Nishida, T.; Yamana, H.; Itoh, K.; Kamura, T. Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers. *J. Immunother.,* **2004,** *27*(1), 60-72.

[50]   Mine, T.; Gouhara, R.; Hida, N.; Imai, N.; Azuma, K.; Rikimaru, T.; Katagiri, K.; Nishikori, M.; Sukehiro, A.; Nakagawa, M.; Yamada, A.; Aizawa, H.; Shirouzu, K.; Itoh, K.; Yamana, H. Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. *Cancer Sci.,* **2003,** *94*(6), 548-556.

[51]   Tanaka, S.; Harada, M.; Mine, T.; Noguchi, M.; Gohara, R.; Azuma, K.; Tamura, M.; Yamada, A.; Morinaga, A.; Nishikori, M.; Katagiri, K.; Itoh, K.; Yamana, H.; Hashimoto, T. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific ctotoxic T-lymphocyte precursors in the periphery. *J. Immunother.,* **2003,** *26*(4), 357-366.

[52]   Sharma, P.; Wagner, K.; Wolchok, J.D.; Allison, J.P. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. *Nat. Rev. Cancer,* **2011,** *11*(11), 805-812.

[53]   Whiteside, T.L. Immune monitoring of clinical trials with biotherapies. *Adv. Clin. Chem.,* **2008,** *45,* 75-97.

[54]   Komatsu, N.; Shichijo, S.; Nakagawa, M.; Itoh, K. New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. *Scand. J. Clin. Lab. Invest.,* **2004,** *64*(6), 535-545.

[55]   Mine, T.; Sato, Y.; Noguchi, M.; Sasatomi, T.; Gouhara, R.; Tsuda, N.; Tanaka, S.; Shomura, H.; Katagiri, K.; Rikimaru, T.; Shichijo, S.; Kamura, T.; Hashimoto, T.; Shirouzu, K.; Yamada, A.; Todo, S.; Itoh, K.; Yamana, H. Humoral responses to peptides correlate with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. *Clin. Cancer Res.,* **2004,** *10*(3), 929-937.

[56]   Noguchi, M.; Uemura, H.; Naito, S.; Akaza, H.; Yamada, A.; Itoh, K. A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. *Prostate,* **2011,** *71*(5), 470-479.

[57]   Terasaki, M.; Shibui, S.; Narita, Y.; Fujimaki, T.; Aoki, T.; Kajiwara, K.; Sawamura, Y.; Kurisu, K.; Mineta, T.; Yamada, A.; Itoh, K. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. *J. Clin. Oncol.,* **2011,** *29*(3), 337-344.

[58]   Noguchi, M.; Kobayashi, K.; Suetsugu, N.; Tomiyasu, K.; Suekane, S.; Yamada, A.; Itoh, K.; Noda, S. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. *Prostate,* **2003,** *57*(1), 80-92.

[59]   Noguchi, M.; Itoh, K.; Suekane, S.; Yao, A.; Suetsugu, N.; Katagiri, K.; Yamada, A.; Yamana, H.; Noda, S. Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer. *Cancer Sci.,* **2004,** *95*(1), 77-84.

[60]   Noguchi, M.; Mine, T.; Yamada, A.; Obata, Y.; Yoshida, K.; Mizoguchi, J.; Harada, M.; Suekane, S.; Itoh, K.; Matsuoka, K. Combination therapy of personalized peptide vaccination and low-dose estramustine phosphate for metastatic hormone refractory prostate cancer patients: an analysis of prognostic factors in the treatment. *Oncol. Res.,* **2007,** *16*(7), 341-349.

[61]   Noguchi, M.; Kakuma, T.; Uemura, H.; Nasu, Y.; Kumon, H.; Hirao, Y.; Moriya, F.; Suekane, S.; Matsuoka, K.; Komatsu, N.; Shichijo, S.; Yamada, A.; Itoh, K. A randomized phase II trial of personalized peptide vaccine plus low dose estramustine phosphate (EMP) versus standard dose EMP in patients with castration resistant prostate cancer. *Cancer Immunol. Immunother.,* **2010,** *59*(7), 1001-1009.

[62]   Noguchi, M.; Moriya, F.; Suekane, S.; Matsuoka, K.; Arai, G.; Matsueda, S.; Sasada, T.; Yamada, A.; Itoh, K. Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy. *Prostate,* **2012,** *72*(8), 834-845.

[63]   Yanagimoto, H.; Mine, T.; Yamamoto, K.; Satoi, S.; Terakawa, N.; Takahashi, K.; Nakahara, K.; Honma, S.; Tanaka, M.; Mizoguchi, J.; Yamada, A.; Oka, M.; Kamiyama, Y.; Itoh, K.; Takai, S. Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer. *Cancer Sci.,* **2007,** *98*(4), 605-611.

[64]   Yanagimoto, H.; Shiomi, H.; Satoi, S.; Mine, T.; Toyokawa, H.; Yamamoto, T.; Tani, T.; Yamada, A.; Kwon, A.H.; Komatsu, N.; Itoh, K.; Noguchi, M. A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. *Oncol. Rep.,* **2010,** *24*(3), 795-801.

[65]   Burris, H.A.; Moore, M.J.; Andersen, J.; Green, M.R.; Rothenberg, M.L.; Modiano, M.R.; Cripps, M.C.; Portenoy, R.K.; Storniolo, A.M.; Tarassoff, P.; Nelson, R.; Dorr, F.A.; Stephens, C.D.; Von Hoff, D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. *J. Clin. Oncol.,* **1997,** *15*(6), 2403-2413.

[66]   Yoshitomi, M.; Yutani, S.; Matsueda, S.; Ioji, T.; Komatsu, N.; Shichijo, S.; Yamada, A.; Itoh, K.; Sasada, T.; Kinoshita, H. Personalized peptide vaccination for advanced biliary tract cancer: IL-6, nutritional status and pre-existing antigen-specific immunity